{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.00001","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.013","value":"0.83"},{"groupId":"OG001","spread":"0.012","value":"0.76"},{"groupId":"OG002","spread":"0.011","value":"0.083"}]}]}],"denomUnitsSelected":"p-phosphate measurements","denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"15"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"240"},{"groupId":"OG002","value":"225"}],"units":"p-phosphate measurements"}],"description":"Blood samples were acquired once every 4 weeks for safety-purposes.","dispersionType":"Standard Error","groups":[{"description":"15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.","id":"OG000","title":"Combined Treatment."},{"description":"16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.","id":"OG001","title":"Denosumab Monotherapy"},{"description":"15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.","id":"OG002","title":"Placebo"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Monthly up to one year.","title":"Mean p-Phosphate During Treatment.","type":"SECONDARY","typeUnitsAnalyzed":"p-phosphate measurements","unitOfMeasure":"pmol/l"}